- Product: Drug targeting Katwijk disease
- Sector: Life Sciences & Health
- Founded: 2017
- Amount invested: € 300,000
- Status: Follow-up financing secured
Drug candidate targeting Katwijk disease
Amylon Therapeutics is developing a drug candidate that targets Katwijk disease, formally called hereditary cerebral haemorrhage with amyloidosis, Dutch type (HCHWA-D). Katwijk disease is a hereditary orphan disease first identified in the Dutch town of Katwijk.